EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma

Bradley E Chipps, Elliot Israel, Richard Beasley, Reynold A Panettieri, Frank C Albers, Robert Rees, Lynn Dunsire, Anna Danilewicz, Eva Johnsson, Christy Cappelletti, Alberto Papi

CHEST · 2023

DOI: 10.1016/j.chest.2023.03.035 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2023. Verfasst von Bradley E Chipps und 10 weiteren Autor:innen. Beteiligte Einrichtung: Capital Allergy and Respiratory Disease Center, Sacramento, CA. Electronic address: bchipps@capitalallergy.com. Hauptthemen laut MEDLINE: Budesonide, Asthma. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the phase 3 MANDALA trial, as-needed albuterol-budesonide pressurized metered-dose inhaler significantly reduced severe exacerbation risk vs as-needed albuterol in patients with moderate-to-severe asthma receiving inhaled corticosteroid-containing maintenance therapy. This study (DENALI) was conducted to address the US Food and Drug Administration combination rule, which requires a combination product to demonstrate that each component contributes to its efficacy. RESEARCH QUESTION: Do both albuterol and budesonide contribute to the efficacy of the albuterol-budesonide combination pressurized metered-dose inhaler in patients with asthma? STUDY DESIGN AND METHODS: This phase 3 double-blind trial randomized patients aged ≥ 12 years with mild-to-moderate asthma 1:1:1:1:1 to four-times-daily albuterol-budesonide 180/160 μg or 180/80 μg, albuterol 180 μg, budesonide 160 μg, or placebo for 12 weeks. Dual-primary efficacy end points included change from baseline in FEV1 area under the curve from 0 to 6 h (FEV1 AUC0-6h) over 12 weeks (assessing albuterol effect) and trough FEV1 at week 12 (assessing budesonide effect). RESULTS: Of 1,001 patients randomized, 989 were ≥ 12 years old and evaluable for efficacy. Change from baseline in FEV1 AUC0-6h over 12 weeks was greater with albuterol-budesonide 180/160 μg vs budesonide 160 μg (least-squares mean [LSM] difference, 80.7 [95% CI, 28.4-132.9] mL; P = .003). Change in trough FEV1 at week 12 was greater with albuterol-budesonide 180/160 and 180/80 μg vs albuterol 180 μg (LSM difference, 132.8 [95% CI, 63.6-201.9] mL and 120.8 [95% CI, 51.5-190.1] mL, respectively; both P < .001). Day 1 time to onset and duration of bronchodilation with albuterol-budesonide were similar to those with albuterol. The albuterol-budesonide adverse event profile was similar to that of the monocomponents. INTERPRETATION: Both monocomponents contributed to albuterol-budesonide lung function efficacy. Albuterol-budesonide was well tolerated, even at regular, relatively high daily doses for 12 weeks, with no new safety findings, supporting its use as a novel rescue therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03847896; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BudesonideAsthmaHumansChildFormoterol FumarateMetered Dose InhalersAdministration, InhalationAlbuterolDouble-Blind MethodBronchodilator AgentsTreatment Outcome

Stichwörter der Autor:innen

albuterol-ICSalbuterol-budesonideasthmabronchodilatorsinflammationinhaled corticosteroidrescue therapyshort-acting β(2)-agonist

Substanzen

BudesonideFormoterol FumarateAlbuterolBronchodilator Agents

Autor:innen und Institutionen

  • Capital Allergy and Respiratory Disease Center, Sacramento, CA. Electronic address: bchipps@capitalallergy.com.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Medical Research Institute of New Zealand, Wellington, New Zealand.
  • Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ.
  • Avillion US Inc., Northbrook, IL.
  • Avillion LLP, London, UK.

Förderung

  • NIEHS NIH HHS
  • AstraZeneca

Zitieren

APA

Chipps, B. E., Israel, E., Beasley, R., Panettieri, R. A., Albers, F. C., Rees, R., Dunsire, L., Danilewicz, A., Johnsson, E., Cappelletti, C., & Papi, A. (2023). Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma. CHEST. https://doi.org/10.1016/j.chest.2023.03.035

Vancouver

Chipps BE, Israel E, Beasley R, Panettieri RA, Albers FC, Rees R, et al. Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma. CHEST. 2023. doi:10.1016/j.chest.2023.03.035

BibTeX
@article{Chipps2023,
  author = {Chipps, Bradley E and Israel, Elliot and Beasley, Richard and Panettieri, Reynold A and Albers, Frank C and Rees, Robert and Dunsire, Lynn and Danilewicz, Anna and Johnsson, Eva and Cappelletti, Christy and Papi, Alberto},
  title = {Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma},
  journal = {CHEST},
  year = {2023},
  doi = {10.1016/j.chest.2023.03.035}
}
Kostenlos starten →